Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albendazole + praziquantel
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination antiparasitic therapy consisting of albendazole and praziquantel. This combination leverages the complementary mechanisms of both drugs to achieve improved efficacy against various parasitic infections, particularly neurocysticercosis and hydatidosis (echinococcosis). Studies have shown that this combination is more effective in destroying viable brain cysts in neurocysticercosis than albendazole alone.
- Other names
- albendazole and praziquantelpraziquantel and albendazole
02
Targets
TUBB (Tubulin (alpha and beta subunits))CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on albendazole + praziquantel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albendazole + praziquantel.